McKesson Corporation (MCK) is trading up at $998.64 (+2.26%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.
Analyst price targets on MCK
One firm's current price target on McKesson Corporation: $933 — 7% below the current $999. Each is tracked to its date and scored the same way a member's call is.
- Wells Fargo $902 → $933 by Aug 2027 Aug 11, 2026 via Investing.com · Wells Fargo's track record
Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.
McKesson Corporation revenue & net income history (FY2017–FY2026)
| FY2017Mar 2017 | FY2018Mar 2018 | FY2019Mar 2019 | FY2020Mar 2020 | FY2021Mar 2021 | FY2022Mar 2022 | FY2023Mar 2023 | FY2024Mar 2024 | FY2025Mar 2025 | FY2026Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $198.5B | $208.4B | $214.3B | $231.1B | $238.2B | $264.0B | $276.7B | $309.0B | $359.1B | $403.4B |
| Growth (year over year) | +4.0% | +4.9% | +2.9% | +7.8% | +3.1% | +10.8% | +4.8% | +11.7% | +16.2% | +12.4% |
| Gross profit | $11.3B | $11.2B | $11.8B | $12.0B | $12.1B | $13.1B | $12.4B | $12.8B | $13.3B | $14.6B |
| Gross margin | 5.7% | 5.4% | 5.5% | 5.2% | 5.1% | 5.0% | 4.5% | 4.2% | 3.7% | 3.6% |
| Operating income | $7.12B | $762.0M | $886.0M | $2.49B | −$5.04B | $2.04B | $4.38B | $3.91B | $4.42B | $6.21B |
| Operating margin | 3.6% | 0.4% | 0.4% | 1.1% | −2.1% | 0.8% | 1.6% | 1.3% | 1.2% | 1.5% |
| Net income | $5.07B | $67.0M | $34.0M | $900.0M | −$4.54B | $1.11B | $3.56B | $3.00B | $3.29B | $4.76B |
| Net margin | 2.6% | 0.0% | 0.0% | 0.4% | −1.9% | 0.4% | 1.3% | 1.0% | 0.9% | 1.2% |
| EPS (diluted) | $22.73 | $0.32 | $0.17 | $4.95 | −$28.26 | $7.23 | $25.03 | $22.39 | $25.72 | $38.38 |
| Balance sheet | ||||||||||
| Cash and equivalents | $2.78B | $2.67B | $2.98B | $4.01B | $6.28B | $3.53B | $4.68B | $4.58B | $5.69B | $3.98B |
| Total assets | $61.0B | $60.4B | $59.7B | $61.2B | $65.0B | $63.3B | $62.3B | $67.4B | $75.1B | $82.3B |
| Total liabilities | $49.7B | $50.3B | $51.4B | $55.9B | $64.8B | $65.1B | $63.8B | $69.0B | $76.8B | $84.1B |
| Long-term debt | $7.30B | $6.75B | $7.26B | $6.33B | $6.41B | $5.08B | $4.63B | $5.58B | $4.46B | $5.26B |
| Shareholders' equity | $11.1B | $9.80B | $8.09B | $5.09B | −$21.0M | −$2.27B | −$1.86B | −$1.97B | −$2.07B | −$2.17B |
| Cash flow | ||||||||||
| Operating cash flow | $4.74B | $4.34B | $4.04B | $4.37B | $4.54B | $4.43B | $5.16B | $4.31B | $6.08B | $6.16B |
| Capital expenditure | $404.0M | $405.0M | $426.0M | $362.0M | $451.0M | $388.0M | $390.0M | $431.0M | $537.0M | $436.0M |
| Free cash flow | $4.34B | $3.94B | $3.61B | $4.01B | $4.09B | $4.05B | $4.77B | $3.88B | $5.55B | $5.72B |
| Dividends paid | $253.0M | $262.0M | $292.0M | $294.0M | $276.0M | $277.0M | $292.0M | $314.0M | $345.0M | $381.0M |
| Share buybacks | $2.31B | $1.71B | $1.64B | $1.93B | $742.0M | $3.52B | $3.64B | $3.02B | $3.15B | $4.75B |
| Q2 FY25Sep 2024 | Q3 FY25Dec 2024 | Q4 FY25†Mar 2025 | Q1 FY26Jun 2025 | Q2 FY26Sep 2025 | Q3 FY26Dec 2025 | Q4 FY26†Mar 2026 | Q1 FY27Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $93.7B | $95.3B | $90.8B | $97.8B | $103.2B | $106.2B | $96.3B | $105.4B |
| Growth (year over year) | +21.3% | +17.8% | +18.9% | +23.4% | +10.1% | +11.4% | +6.0% | +7.7% |
| Gross profit | $3.25B | $3.28B | $3.64B | $3.28B | $3.54B | $3.69B | $4.04B | $3.69B |
| Gross margin | 3.5% | 3.4% | 4.0% | 3.4% | 3.4% | 3.5% | 4.2% | 3.5% |
| Operating income | $578.0M | $1.22B | $1.59B | $1.04B | $1.41B | $1.62B | $2.15B | $1.32B |
| Operating margin | 0.6% | 1.3% | 1.8% | 1.1% | 1.4% | 1.5% | 2.2% | 1.3% |
| Net income | $241.0M | $879.0M | $1.26B | $784.0M | $1.11B | $1.19B | $1.68B | $614.0M |
| Net margin | 0.3% | 0.9% | 1.4% | 0.8% | 1.1% | 1.1% | 1.7% | 0.6% |
| EPS (diluted) | $1.87 | $6.95 | $9.90 | $6.25 | $8.92 | $9.59 | $13.62 | $5.15 |
| Balance sheet | ||||||||
| Cash and equivalents | $2.51B | $1.13B | $5.69B | $2.42B | $4.00B | $2.96B | $3.98B | $5.16B |
| Total assets | $72.4B | $71.1B | $75.1B | $81.3B | $84.2B | $84.2B | $82.3B | $88.3B |
| Total liabilities | $75.1B | $73.8B | $76.8B | $82.9B | $85.5B | $85.1B | $84.1B | $92.2B |
| Long-term debt | $5.69B | $4.42B | $4.46B | $6.53B | $6.01B | $5.42B | $5.26B | $8.43B |
| Shareholders' equity | −$3.02B | −$3.08B | −$2.07B | −$1.97B | −$1.74B | −$1.30B | −$2.17B | −$4.24B |
| Cash flow | ||||||||
| Operating cash flow | $2.10B | −$2.38B | $7.75B | −$918.0M | $2.42B | $1.23B | $3.42B | −$220.0M |
| Capital expenditure | $136.0M | $126.0M | $169.0M | $111.0M | $106.0M | $108.0M | $111.0M | $112.0M |
| Free cash flow | $1.96B | −$2.51B | $7.58B | −$1.03B | $2.31B | $1.12B | $3.31B | −$332.0M |
| Dividends paid | $80.0M | $92.0M | $91.0M | $90.0M | $89.0M | $101.0M | $101.0M | $102.0M |
| Share buybacks | $1.49B | $827.0M | $300.0M | $581.0M | $818.0M | $680.0M | $2.67B | $2.53B |
From McKesson Corporation's 10-K and 10-Q filings with the SEC; its fiscal year ends in March. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About McKesson Corporation
McKesson Corporation is an American publicly traded company that distributes pharmaceuticals and provides health information technology, medical supplies, and health management tools. The company delivers a third of all pharmaceutical products used or consumed in North America and employs over 80,000 employees. With $308.9 billion in 2024 revenue, it is the ninth-largest company by revenue in the United States and the nation's largest health care company. The company is headquartered in Irving, Texas. It is a component of the S&P 500 and is listed on the New York Stock Exchange, where it is traded under the ticker symbol "MCK".
- Headquarters
- Irving, Texas From SEC filings, Oct 2026
Recent News (20)
-
Option Care Stock Trades Below McKesson's Deal Price — Here's the Spread Option Care Stock Trades Below McKesson's Deal Price — Here's the Spread Benzinga
-
OPCH shares jump 34% as CD&R, McKesson agree to $5.8B takeover (OPCH:NASDAQ) OPCH shares jump 34% as CD&R, McKesson agree to $5.8B takeover (OPCH:NASDAQ) Seeking Alpha
-
McKesson extends CVS deal; shares rise
McKesson extends CVS deal; shares rise
-
Alluvium Raised Its McKesson (MCK) Stake as Long-Term Growth Expectations Remain Strong
Alluvium Raised Its McKesson (MCK) Stake as Long-Term Growth Expectations Remain Strong
-
McKesson Raises Outlook, Eyes Oncology Growth With Precision Medicine Deal
McKesson Raises Outlook, Eyes Oncology Growth With Precision Medicine Deal
-
McKesson at Morgan Stanley conference: outlook rises on oncology push
McKesson at Morgan Stanley conference: outlook rises on oncology push
-
McKesson Eyes $2.25B Precision Medicine Deal as Oncology Growth Accelerates
McKesson Eyes $2.25B Precision Medicine Deal as Oncology Growth Accelerates
-
McKesson Bets $2.25 Billion More on Oncology With Precision Medicine Buy
McKesson Bets $2.25 Billion More on Oncology With Precision Medicine Buy
-
McKesson Stock: Is MCK Outperforming the Healthcare Sector?
McKesson Stock: Is MCK Outperforming the Healthcare Sector?
-
Hackers claim millions of patient records stolen during data breach at healthcare giant McKesson The company, which distributes medicines and medical devices to hospitals and healthcare practices across the U.S., said it was hacked and expects intermittent service degradation.
-
McKesson Corporation (MCK) Doubles Down on Healthcare Growth With Precision Medicine Acquisition
McKesson Corporation (MCK) Doubles Down on Healthcare Growth With Precision Medicine Acquisition
-
McKesson to acquire Precision Medicine Group for $2.25bn
McKesson to acquire Precision Medicine Group for $2.25bn
-
McKesson stock jumps on $2.25B Precision Medicine deal
McKesson stock jumps on $2.25B Precision Medicine deal
-
McKesson to acquire Precision Medicine Group for $2.25 billion
McKesson to acquire Precision Medicine Group for $2.25 billion
-
McKesson Buys Precision Medicine to Expand Clinical Research and Commercialization
McKesson Buys Precision Medicine to Expand Clinical Research and Commercialization
-
McKesson Stock Outlook: Is Wall Street Bullish or Bearish?
McKesson Stock Outlook: Is Wall Street Bullish or Bearish?
-
McKesson director Bradley Lerman sells $268,589 in shares
McKesson director Bradley Lerman sells $268,589 in shares
-
Wells Fargo raises McKesson stock price target on earnings outlook Wells Fargo raises McKesson stock price target on earnings outlook Investing.com
-
McKesson Q1 Earnings Call Highlights McKesson Q1 Earnings Call Highlights
-
More Health Care stocks
- ISRG Intuitive Surgical
- JNJ Johnson & Johnson
- LH Labcorp
- LLY Lilly (Eli)
- MDT Medtronic
- MRK Merck & Co.
- MRNA Moderna
- MTD Mettler Toledo